Cancer Research · 2015 · 119 citations · 48 references
Life SciencesMolecular BiologyOncologyApoptosisEpigeneticsMolecular OncologyApoptosis In CancerApoptosis PharmacologyApoptosis RegulationCancer EpigeneticsChromatinEpigenetic Regulation In CancerAcute Myeloid Leukemia TherapyCdk InhibitorsChromatin RemodelingEpigenetic Targeted AgentsHistone DeacetylasesHistone MethyltransferasesLeukemia-associated Fusion GenesOncogenic Fusion Proteins
MLL gene translocations, present in 60–80% of infant acute leukemias, drive poor prognosis by recruiting epigenetic regulators that remodel chromatin and activate tumorigenic programs. The study aimed to identify small‑molecule inhibitors of epigenetic and transcriptional regulators that could trigger apoptosis in MLL‑AF9‑driven AML cells. A screening approach was applied to genetically engineered mouse models of MLL‑AF9 AML, testing candidate compounds for apoptotic activity. Dinaciclib, a CDK inhibitor, and panobinostat, an HDAC inhibitor, were the most potent inducers of apoptosis in vitro; dinaciclib rapidly reduced Mcl‑1 expression, and its antitumor efficacy in mouse xenografts prolonged survival, supporting CDK inhibition as a promising therapy for MLL‑rearranged AML.
Translocations of the mixed lineage leukemia (MLL) gene occur in 60% to 80% of all infant acute leukemias and are markers of poor prognosis. MLL-AF9 and other MLL fusion proteins aberrantly recruit epigenetic regulatory proteins, including histone deacetylases (HDAC), histone methyltransferases, bromodomain-containing proteins, and transcription elongation factors to mediate chromatin remodeling and regulate tumorigenic gene expression programs. We conducted a small-molecule inhibitor screen to test the ability of candidate pharmacologic agents targeting epigenetic and transcriptional regulatory proteins to induce apoptosis in leukemic cells derived from genetically engineered mouse models of MLL-AF9-driven acute myeloid leukemia (AML). We found that the CDK inhibitor dinaciclib and HDAC inhibitor panobinostat were the most potent inducers of apoptosis in short-term in vitro assays. Treatment of MLL-rearranged leukemic cells with dinaciclib resulted in rapidly decreased expression of the prosurvival protein Mcl-1, and accordingly, overexpression of Mcl-1 protected AML cells from dinaciclib-induced apoptosis. Administration of dinaciclib to mice bearing MLL-AF9-driven human and mouse leukemias elicited potent antitumor responses and significantly prolonged survival. Collectively, these studies highlight a new therapeutic approach to potentially overcome the resistance of MLL-rearranged AML to conventional chemotherapies and prompt further clinical evaluation of CDK inhibitors in AML patients harboring MLL fusion proteins.
48
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Johannes Zuber, Junwei Shi, Eric Wang et al. · Nature · 2011 · 1.9K citations
Transcriptional Amplification in Tumor Cells with Elevated c-Myc
Charles Y. Lin, Jakob Lovén, Peter B. Rahl et al. · Cell · 2012 · 1.6K citations · Full text
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A. Dawson, Rab K. Prinjha, Antje Dittmann et al. · Nature · 2011 · 1.5K citations · Full text